By this, SGLT-2-inhibition has been established as a first-line treatment besides metformin (only if eGFR is >30 mL/min/1.73 m2), RAS-inhibition, and statin-therapy in individuals with DM at renal risk. This evidence concerns the gene SLC5A2 and diabetes mellitus.